Abstract: The current invention provides a method of activating fibroblast and myofibroblast apoptosis in a tissue of a mammal, comprising administering to the tissue a therapeutically effective amount of a composition comprising an siRNA molecule that binds to an mRNA that codes for TGFB1 protein in a mammalian cell, an siRNA molecule that binds to an mRNA that codes for COX-2 protein in a mammalian cell, and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable histidine-lysine polymer. The invention also provides additional methods for using this composition.
Type:
Grant
Filed:
October 30, 2017
Date of Patent:
July 11, 2023
Assignees:
Sirnaomics, Inc., Sirnaomics Medicine Technology (Suzhou) Co, Ltd.
Inventors:
John Xu, Patrick Y. Lu, Jia Zhou, Qingfeng Li, Vera Simonenko